Preparation of synthetic bovine parathyroid hormone fragment 1-34 for parenteral use in human studies

W. M. Law, R. A. Nissenson, G. G. Klee, H. Heath

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is growing interest in use of synthetic parathyroid hormone peptides such as the aminoterminal 1-34 fragment (PTH 1-34) in human studies, since bovine parathyroid extract is no longer commercially available. We found no data concerning how to sterilize and dilute the synthetic bovine PTH 1-34 (bPTH 1-34) to minimize adsorptive losses and maximize conservation of bioactivity. Therefore, we examined adsorptive losses of electrolytically-labelled, biologically-active bPTH 1-34 onto sterile filtration devices (Millex GV, Millipore Corp.) in solutions of 0.1 M acetic acid containing varying human serum albumin (HSA) concentrations (0.1-5.0%, w/v) and varying hormone concentrations (1-50 μg bPTH 1-34/ml). We also assessed preservation of bPTH 1-34 bioactivity (canine renal cortical plasma membranes) in diluted, sterile-filtered solutions refrigerated for 4 days. Adsorptive losses were inversely related to bPTH 1-34 concentration, being least with 50 μg bPTH 1-34/ml, at all concentrations of HSA. Losses during filtration were essentially indistinguishable at HSA concentrations of 0.1-1.0%, but were, surprisingly, increased by 2.5 and 5.0% HSA. There were no important differences in adsorptive losses among five different lots of Millex-GV filters. Full bioactivity was preserved over 4 days of refrigeration at a bPTH 1-34 concentration of 20 μg/ml. The data suggest that bPTH 1-34 should be sterile-filtered at a concentration of ≥ 20 μg/ml in 0.1 M acetic acid containing 0.1-1.0% HSA. Such sterile solutions are stable at 4°C for at least 4 days.

Original languageEnglish (US)
Pages (from-to)1335-1337
Number of pages3
JournalJournal of Clinical Endocrinology and Metabolism
Volume56
Issue number6
StatePublished - 1983

Fingerprint

Parathyroid Hormone
Serum Albumin
Bioactivity
Acetic Acid
bovine parathyroid hormone
bovine parathyroid hormone (1-34)
Refrigeration
Cell membranes
Conservation
Canidae
Hormones
Cell Membrane
Kidney
Equipment and Supplies
Peptides

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Preparation of synthetic bovine parathyroid hormone fragment 1-34 for parenteral use in human studies. / Law, W. M.; Nissenson, R. A.; Klee, G. G.; Heath, H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 56, No. 6, 1983, p. 1335-1337.

Research output: Contribution to journalArticle

Law, W. M. ; Nissenson, R. A. ; Klee, G. G. ; Heath, H. / Preparation of synthetic bovine parathyroid hormone fragment 1-34 for parenteral use in human studies. In: Journal of Clinical Endocrinology and Metabolism. 1983 ; Vol. 56, No. 6. pp. 1335-1337.
@article{32f409066f54409a8f4909d74ec0c50c,
title = "Preparation of synthetic bovine parathyroid hormone fragment 1-34 for parenteral use in human studies",
abstract = "There is growing interest in use of synthetic parathyroid hormone peptides such as the aminoterminal 1-34 fragment (PTH 1-34) in human studies, since bovine parathyroid extract is no longer commercially available. We found no data concerning how to sterilize and dilute the synthetic bovine PTH 1-34 (bPTH 1-34) to minimize adsorptive losses and maximize conservation of bioactivity. Therefore, we examined adsorptive losses of electrolytically-labelled, biologically-active bPTH 1-34 onto sterile filtration devices (Millex GV, Millipore Corp.) in solutions of 0.1 M acetic acid containing varying human serum albumin (HSA) concentrations (0.1-5.0{\%}, w/v) and varying hormone concentrations (1-50 μg bPTH 1-34/ml). We also assessed preservation of bPTH 1-34 bioactivity (canine renal cortical plasma membranes) in diluted, sterile-filtered solutions refrigerated for 4 days. Adsorptive losses were inversely related to bPTH 1-34 concentration, being least with 50 μg bPTH 1-34/ml, at all concentrations of HSA. Losses during filtration were essentially indistinguishable at HSA concentrations of 0.1-1.0{\%}, but were, surprisingly, increased by 2.5 and 5.0{\%} HSA. There were no important differences in adsorptive losses among five different lots of Millex-GV filters. Full bioactivity was preserved over 4 days of refrigeration at a bPTH 1-34 concentration of 20 μg/ml. The data suggest that bPTH 1-34 should be sterile-filtered at a concentration of ≥ 20 μg/ml in 0.1 M acetic acid containing 0.1-1.0{\%} HSA. Such sterile solutions are stable at 4°C for at least 4 days.",
author = "Law, {W. M.} and Nissenson, {R. A.} and Klee, {G. G.} and H. Heath",
year = "1983",
language = "English (US)",
volume = "56",
pages = "1335--1337",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Preparation of synthetic bovine parathyroid hormone fragment 1-34 for parenteral use in human studies

AU - Law, W. M.

AU - Nissenson, R. A.

AU - Klee, G. G.

AU - Heath, H.

PY - 1983

Y1 - 1983

N2 - There is growing interest in use of synthetic parathyroid hormone peptides such as the aminoterminal 1-34 fragment (PTH 1-34) in human studies, since bovine parathyroid extract is no longer commercially available. We found no data concerning how to sterilize and dilute the synthetic bovine PTH 1-34 (bPTH 1-34) to minimize adsorptive losses and maximize conservation of bioactivity. Therefore, we examined adsorptive losses of electrolytically-labelled, biologically-active bPTH 1-34 onto sterile filtration devices (Millex GV, Millipore Corp.) in solutions of 0.1 M acetic acid containing varying human serum albumin (HSA) concentrations (0.1-5.0%, w/v) and varying hormone concentrations (1-50 μg bPTH 1-34/ml). We also assessed preservation of bPTH 1-34 bioactivity (canine renal cortical plasma membranes) in diluted, sterile-filtered solutions refrigerated for 4 days. Adsorptive losses were inversely related to bPTH 1-34 concentration, being least with 50 μg bPTH 1-34/ml, at all concentrations of HSA. Losses during filtration were essentially indistinguishable at HSA concentrations of 0.1-1.0%, but were, surprisingly, increased by 2.5 and 5.0% HSA. There were no important differences in adsorptive losses among five different lots of Millex-GV filters. Full bioactivity was preserved over 4 days of refrigeration at a bPTH 1-34 concentration of 20 μg/ml. The data suggest that bPTH 1-34 should be sterile-filtered at a concentration of ≥ 20 μg/ml in 0.1 M acetic acid containing 0.1-1.0% HSA. Such sterile solutions are stable at 4°C for at least 4 days.

AB - There is growing interest in use of synthetic parathyroid hormone peptides such as the aminoterminal 1-34 fragment (PTH 1-34) in human studies, since bovine parathyroid extract is no longer commercially available. We found no data concerning how to sterilize and dilute the synthetic bovine PTH 1-34 (bPTH 1-34) to minimize adsorptive losses and maximize conservation of bioactivity. Therefore, we examined adsorptive losses of electrolytically-labelled, biologically-active bPTH 1-34 onto sterile filtration devices (Millex GV, Millipore Corp.) in solutions of 0.1 M acetic acid containing varying human serum albumin (HSA) concentrations (0.1-5.0%, w/v) and varying hormone concentrations (1-50 μg bPTH 1-34/ml). We also assessed preservation of bPTH 1-34 bioactivity (canine renal cortical plasma membranes) in diluted, sterile-filtered solutions refrigerated for 4 days. Adsorptive losses were inversely related to bPTH 1-34 concentration, being least with 50 μg bPTH 1-34/ml, at all concentrations of HSA. Losses during filtration were essentially indistinguishable at HSA concentrations of 0.1-1.0%, but were, surprisingly, increased by 2.5 and 5.0% HSA. There were no important differences in adsorptive losses among five different lots of Millex-GV filters. Full bioactivity was preserved over 4 days of refrigeration at a bPTH 1-34 concentration of 20 μg/ml. The data suggest that bPTH 1-34 should be sterile-filtered at a concentration of ≥ 20 μg/ml in 0.1 M acetic acid containing 0.1-1.0% HSA. Such sterile solutions are stable at 4°C for at least 4 days.

UR - http://www.scopus.com/inward/record.url?scp=0020606292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020606292&partnerID=8YFLogxK

M3 - Article

C2 - 6841565

AN - SCOPUS:0020606292

VL - 56

SP - 1335

EP - 1337

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -